A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of β-caryophyllene, a dietary cannabinoid.

@article{Hashiesh2021AFR,
  title={A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of $\beta$-caryophyllene, a dietary cannabinoid.},
  author={Hebaallah Mamdouh Hashiesh and Charu Sharma and Sameer N Goyal and Bassem Sadek and Niraj Kumar Jha and Juma Al Kaabi and Shreesh Kumar Ojha},
  journal={Biomedicine \& pharmacotherapy = Biomedecine \& pharmacotherapie},
  year={2021},
  volume={140},
  pages={
          111639
        }
}
View on PubMed
doi.org
4 Citations
Highly Influential Citations
1
Background Citations
1

4 Citations

Citation Type

Citation Type

Beta-Caryophyllene Exhibits Anti-Proliferative Effects through Apoptosis Induction and Cell Cycle Modulation in Multiple Myeloma Cells
TLDR
Investigating the antitumor effect of beta-caryophyllene (BCP), a CB2R agonist, in an in vitro model of multiple myeloma revealed that BCP might have significant and effective anti-cancer and anti-proliferative effects in MM cells by activating apoptosis, modulating different molecular pathways, and downregulating the cell cycle.
Protective antioxidative and anti-inflammatory actions of β-caryophyllene against sulfasalazine-induced nephrotoxicity in rat
TLDR
This study is the first to link NF-κB, TGF-β, Nrf2, AMPK, and AKT with SFZ-induced nephrotoxicity and reveal antioxidative and anti-inflammatory effects for BCP againstSFZ-associated nephropathy.
Multi-Target Approach of Murraya koenigii Leaves in Treating Neurodegenerative Diseases
TLDR
An overview of literature concerning the mechanisms of action and the safety profile of significant bioactive components present in M. koenigii leaves are presented to support further investigations into their neuroprotective therapeutic potential.
Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome

References

SHOWING 1-10 OF 322 REFERENCES
β-Caryophyllene, a natural bicyclic sesquiterpene attenuates doxorubicin-induced chronic cardiotoxicity via activation of myocardial cannabinoid type-2 (CB2) receptors in rats.
CB2 Cannabinoid Receptors as a Therapeutic Target—What Does the Future Hold?
TLDR
This review summarizes the present knowledge of CB2 receptor signaling, localization, and regulation, and discusses the availability of genetic tools to study CB2 receptors and also provides an update on preclinical data on CB2 agonists in pain models.
Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products
TLDR
It is expected that more novel cannabinoids will be discovered and forecasted as promising drug leads from diverse natural sources and species, such as animal venoms which constitute a true pharmacopeia of toxins modulating diverse targets, with astonishing affinity and selectivity.
Antiinflammatory cannabinoids in diet – towards a better understanding of CB2 receptor action?
  • J. Gertsch
  • Biology
    Communicative & integrative biology
  • 2008
TLDR
In this addendum, the CB2 receptor-dependent effect of beta-caryophyllene on LPS-triggered activation of the kinases Erk1/2 and JNK 1/2 are further discussed with respect to the possibility that both CB2 inverse agonists and agonists, independent of their G-protein signalling, may block LPS’s activation of MAPKs, leading to inhibition of proinflammatory cytokine expression and attenuation of inflammation.
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
TLDR
It is believed that selective CB2 agonism may afford a superior analgesic agent devoid of the centrally mediated CB1 effects, and high value putative therapeutics for treating pain and other disease states are represented.
[The cannabinoid system and pain: towards new drugs?].
  • M. Beltramo
  • Biology, Medicine
    Journal de la Societe de biologie
  • 2009
TLDR
CB2 agonists are probably acting through several mechanisms and thus CB2 represents an interesting and promising target in the chronic pain field and further clarification of the mechanisms at the basis of CB2 analgesic effect would surely be an intriguing and stimulating area of research for the years to come.
The endocannabinoid system: Its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation
Pharmacological Characterization of a Novel Cannabinoid Ligand, MDA19, for Treatment of Neuropathic Pain
TLDR
It is found that MDA19 exhibited a distinctive in vitro functional profile at rat CB2 receptors and behaved as a CB1/CB2 agonist in vivo, characteristics of a protean agonist.
(−)-β-Caryophyllene, a CB2 Receptor-Selective Phytocannabinoid, Suppresses Motor Paralysis and Neuroinflammation in a Murine Model of Multiple Sclerosis
TLDR
It is demonstrated that BCP significantly ameliorates both the clinical and pathological parameters of EAE and strongly supports the effectiveness of BCP as a novel molecule to target in the development of effective therapeutic agents for MS.
β-Caryophyllene, a CB2-Receptor-Selective Phytocannabinoid, Suppresses Mechanical Allodynia in a Mouse Model of Antiretroviral-Induced Neuropathic Pain
TLDR
Investigating the effect of β-caryophyllene (BCP), a CB2-selective phytocannabinoid, in a model of NRTI-induced neuropathic pain concluded that BCP could be useful for prevention and treatment of antiretroviral-induced Neuropathic pain.
...
1
2
3
4
5
...